Source:http://linkedlifedata.com/resource/pubmed/id/14675350
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2003-12-16
|
| pubmed:abstractText |
To determine the feasibility and toxicity of a chemoimmunotherapy regimen in combination with radiotherapy in stage IIIB cervical cancer patients, cisplatin 10-20 mg/m(2) intravenous (iv) weekly, 5-fluorouracil (5FU) 500 mg/m(2) (24-h infusion) weekly, interferon alpha-2a 3 MU subcutaneously 3 days a week, and 13-cis-retinoic acid 0.5 mg/kg/day orally were given in concurrence with 8-week period of radiotherapy and continued for another 4 weeks after finishing radiotherapy. The dose of cisplatin was escalated from 10 mg/m2 in the first group of three patients (level 1) to 15 mg/m(2) in the second group of three patients (level 2) and to 20 mg/m(2) in the third group of two patients (level 3) if the former groups could tolerate the drugs well. Patients in levels 1 and 2 had tolerable toxicities. Two patients in level 3 experienced grade 4 leukopenia, so chemoimmunotherapy was discontinued after 2 and 3 cycles orderly. After recovery from toxicities, they continued with radiotherapy. In conclusion, cisplatin 15 mg/m2, 5-FU 500 mg/m(2) weekly, interferon alpha-2a 3 MU subcutaneously 3 days a week, and 13-cis-retinoic acid 0.5 mg/kg/day orally in combination with radiotherapy in stage IIIB cervical cancer patients is tolerable. Leukopenia is the dose-limiting toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Isotretinoin,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1048-891X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
652-6
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:14675350-Administration, Oral,
pubmed-meshheading:14675350-Adult,
pubmed-meshheading:14675350-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14675350-Cisplatin,
pubmed-meshheading:14675350-Combined Modality Therapy,
pubmed-meshheading:14675350-Drug Administration Schedule,
pubmed-meshheading:14675350-Female,
pubmed-meshheading:14675350-Fluorouracil,
pubmed-meshheading:14675350-Humans,
pubmed-meshheading:14675350-Immunotherapy,
pubmed-meshheading:14675350-Infusions, Intravenous,
pubmed-meshheading:14675350-Injections, Subcutaneous,
pubmed-meshheading:14675350-Interferon-alpha,
pubmed-meshheading:14675350-Isotretinoin,
pubmed-meshheading:14675350-Middle Aged,
pubmed-meshheading:14675350-Neoplasm Staging,
pubmed-meshheading:14675350-Radiotherapy, Adjuvant,
pubmed-meshheading:14675350-Recombinant Proteins,
pubmed-meshheading:14675350-Treatment Outcome,
pubmed-meshheading:14675350-Uterine Cervical Neoplasms
|
| pubmed:articleTitle |
Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients.
|
| pubmed:affiliation |
Department of Obstetrics and Gynaecology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. rasw1@mahidol.ac.th
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|